8 results match your criteria: "National Reference Center for Herpesviruses (NRCHV)[Affiliation]"
Reliability of QuantiFERON®-CMV in predicting CMV recurrence in heart transplant recipients: A single-center retrospective study.
Clin Transplant
December 2023
Service des maladies infectieuses et tropicales, CHU Lille, Lille, France.
Article Synopsis
- The study aimed to evaluate whether the QuantiFERON®-CMV test could predict CMV recurrence in heart transplant recipients and improve the management of secondary prophylaxis duration.
- Out of 15 patients with CMV infection, 33% experienced recurrence, but the QuantiFERON®-CMV test did not significantly correlate with recurrence rates or the length of prophylaxis.
- The findings suggest that the QuantiFERON®-CMV assay may not be effective for predicting CMV recurrence in this patient group, indicating a need for alternative tests and treatment strategies, such as using everolimus in immunosuppressive regimens.
Identification of a leucine-zipper motif in pUL51 essential for HCMV replication and potential target for antiviral development.
Antiviral Res
September 2023
Univ. Limoges, INSERM, CHU Limoges, RESINFIT, U1092, F-87000, Limoges, France; CHU Limoges, Laboratoire de Bactériologie-Virologie-Hygiène, National Reference Center for Herpesviruses (NRCHV), F-87000, Limoges, France. Electronic address:
Human cytomegalovirus (HCMV) can cause serious diseases in immunocompromised patients. Use of current antivirals is limited by their adverse effects and emergence of drug resistance mutations. Thus, new drugs are an urgent need.
View Article and Find Full Text PDFCytomegalovirus in donors for fecal microbiota transplantation, the phantom menace?
PLoS One
July 2023
Laboratoire de Bactériologie-Virologie-Hygiène, National Reference Center for Herpesviruses (NRCHV), CHU Limoges, Limoges, France.
Background: Fecal Microbiota Transplantation (FMT) has become the preferred treatment for recurrent Clostridioides difficile Infections (CDI). However, donor screening is a complex process that varies between countries. The primary objective of screening is to prevent the transfer of potential pathogens from the donor to the recipient via feces.
View Article and Find Full Text PDFFirst clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure.
Antiviral Res
August 2022
Univ. Limoges, INSERM, CHU Limoges, RESINFIT, U1092, F-87000, Limoges, France; CHU Limoges, Laboratoire de Bactériologie-Virologie-Hygiène, National Reference Center for Herpesviruses (NRCHV), F-87000, Limoges, France. Electronic address:
Background: Letermovir (LMV) is a human cytomegalovirus (HCMV) terminase inhibitor indicated as prophylaxis for HCMV-positive stem-cell recipients. Its mechanism of action involves at least the viral terminase proteins pUL56, pUL89 and pUL51. Despite its efficiency, resistance mutations were characterized in vitro and in vivo, largely focused on pUL56.
View Article and Find Full Text PDFTowards a Prophylactic Vaccine for the Prevention of HCMV Infection.
Vaccines (Basel)
August 2021
INSERM, CHU Limoges, University of Limoges, RESINFIT, U1092, 87000 Limoges, France.
Human cytomegalovirus (HCMV) or human herpesvirus 5, is a ubiquitous human herpesvirus, which can cause severe disease in immunocompromised patients (AIDS patients and solid organ transplant or hematopoietic stem cell transplant recipients) [...
View Article and Find Full Text PDFNew Insights into Human Cytomegalovirus pUL52 Structure.
Viruses
August 2021
INSERM, CHU Limoges, University of Limoges, RESINFIT, U1092, F-87000 Limoges, France.
Human cytomegalovirus (HCMV) can cause serious diseases in immunocompromised patients. Current antiviral inhibitors all target the viral DNA polymerase. They have adverse effects, and prolonged treatment can select for drug resistance mutations.
View Article and Find Full Text PDFStructures and Divergent Mechanisms in Capsid Maturation and Stabilization Following Genome Packaging of Human Cytomegalovirus and Herpesviruses.
Life (Basel)
February 2021
INSERM, CHU Limoges, University of Limoges, RESINFIT, U1092, 87000 Limoges, France.
Article Synopsis
- Herpesviruses cause various diseases, often mild in healthy individuals but severe in those with weakened immune systems.
- Current treatments mainly focus on blocking viral DNA polymerase, with limited effectiveness against some herpesviruses like Epstein-Barr and human herpesvirus 8.
- There is a need for new antiviral drugs that target different stages of the virus lifecycle, such as capsid assembly and DNA packaging, to improve treatment options and reduce side effects.
Highlighting of a LAGLIDADG and a Zing Finger Motifs Located in the pUL56 Sequence Crucial for HCMV Replication.
Viruses
November 2019
UMR 1092, INSERM, CHU Limoges, Université Limoges, F-87000 Limoges, France.
The human cytomegalovirus (HCMV) terminase complex is part of DNA-packaging machinery that delivers a unit-length genome into a procapsid. Sequence comparison of herpesvirus homologs allowed us to identify a potential LATLNDIERFL and zinc finger pattern in N-terminal part of pUL56. Recombinant viruses were generated with specific serine or alanine substitutions in these putative patterns.
View Article and Find Full Text PDF